According to filings with the U.S. Securities and Exchange Commission, Eikonoklastes Therapeutics is raising up to $8,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Bruce Halpryn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Eikonoklastes Therapeutics
Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment. It has recently been discovered that certain pathological cells but not healthy cells including cancers with high unmet need and high mortality such as triple negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors, express tissue factor on the surface of their cell membranes. Several other non cancerous indications such as endometriosis also highly and selectively express tissue factor.

To learn more about Eikonoklastes Therapeutics, visit http://eikonoklastes.com/
Company Linkedin Page: https://www.linkedin.com/company/eikonoklastes-therapeutics-inc/

Contact:
Bruce Halpryn, President and Chief Executive Officer
513-549-6484
https://www.linkedin.com/in/brucehalpryn/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.